Basic Information

Email Address

• Email Address

  funazo.tomoko.4fkyoto-u.ac.jp

Professional Memberships

• From 2018, To Present

  European Society for Medical Oncology
• From 2017, To Present

  American Association for Cancer Research
• From 2016, To Present

  Japanese Cancer Association
• From 2016, To Present

  The Japan Lung Cancer Society
• From 2014, To Present

  The Japanese Association for Infectious Diseases
• From 2014, To Present

  The Japan Society for Respiratory Endoscopy
• From 2013, To Present

  The Japanese Respiratory Society
• From 2012, To Present

  The Japanese Society of Internal Medicine

Academic Degree

• 23 Sep. 2020

  Ph.D. in Medicine, Kyoto University

Academic Resume (Graduate Schools)

• Kyoto University, 大学院医学研究科博士課程医学専攻, Department of Respiratory Medicine, 研究指導認定退学
• Kyoto University, Graduate School of Medicine, Department of Respiratory Medicine, Completed Doctoral Program

Academic Resume (Undergraduate School/Majors)

• 神戸大学, 医学部医学科, 卒業

Research History

• From Apr. 2022, To Present

  Japan Society for the Promotion of Science, 特別研究員（RPD)
• From Jan. 2022, To Mar. 2022

  京都大学医学部付属病院, 呼吸器内科, キャリア支援診療医
• From Apr. 2018, To Mar. 2020

  Japan Society for the Promotion of Science, 特別研究員（DC）
• From Apr. 2011, To Mar. 2016

  大阪赤十字病院, レジデント

ID,URL

• ORCID ID

  0000-0003-2152-2150

• J-Global ID

  202301012851436916

• Researcher number

  50970042

researchmap URL

• https://researchmap.jp/funazo

Research

Research Areas

• Life sciences, Tumor diagnostics and therapeutics
• Life sciences, Respiratory medicine

Papers

• Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study

  Yusuke Shima; Hironori Yoshida; Keiichiro Suminaga; Hiroshi Yoshida; Kentaro Hashimoto; Tatsuya Ogimoto; Kazutaka Hosoya; Hitomi Ajimizu; Tomoko Funazo; Takashi Nomizo; Hiroaki Ozasa; Toyohiro Hirai

  BMC Cancer, 04 Mar. 2025

  Access this paper :

  
• 新たな肺腺癌脳転移モデルを用いた抗PD-1/CTLA-4抗体併用療法の有効性と作用機序の検討(Novel Model of Lung Adenocarcinoma Brain Metastasis Reveals Efficacy of Anti-PD-1/CTLA-4 Combination Therapy)

  細谷 和貴; 小笹 裕晃; 辻 貴宏; 島 佑介; 住永 圭一郎; 橋本 健太郎; 吉田 寛; 味水 瞳; 船造 智子; 吉田 博徳; 野溝 岳; 和氣 弘明; 平井 豊博; 辻 貴宏

  日本癌学会総会記事, Sep. 2024

  
• ALK肺がんにおける分子標的薬に対するTEAD阻害薬の併用効果のバイオマーカー探索(Biomarkers for Efficacy of TEAD Inhibitor Combination with Molecularly targeted drugs in ALK Lung Cancer)

  橋本 健太郎; 小笹 裕晃; 島 佑介; 住永 圭一郎; 吉田 寛; 細谷 和貴; 船造 智子; 味水 瞳; 吉田 博徳; 野溝 岳; Tang Tracy T.; 平井 豊博; 小笹 裕晃

  日本癌学会総会記事, Sep. 2024

  
• 新たな肺腺癌脳転移モデルを用いた抗PD-1/CTLA-4抗体併用療法の有効性と作用機序の検討(Novel Model of Lung Adenocarcinoma Brain Metastasis Reveals Efficacy of Anti-PD-1/CTLA-4 Combination Therapy)

  細谷 和貴; 小笹 裕晃; 辻 貴宏; 島 佑介; 住永 圭一郎; 橋本 健太郎; 吉田 寛; 味水 瞳; 船造 智子; 吉田 博徳; 野溝 岳; 和氣 弘明; 平井 豊博; 辻 貴宏

  日本癌学会総会記事, Sep. 2024

  
• Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer

  Tatsuya Ogimoto; Hiroaki Ozasa; Takahiro Tsuji; Tomoko Funazo; Masatoshi Yamazoe; Kentaro Hashimoto; Hiroshi Yoshida; Kazutaka Hosoya; Hitomi Ajimizu; Takashi Nomizo; Hironori Yoshida; Masatsugu Hamaji; Toshi Menju; Akihiko Yoshizawa; Hiroshi Date; Toyohiro Hirai

  Molecular Cancer Therapeutics, 06 Dec. 2023

  
• 新規TEAD1阻害薬VT103とDabrafenibの併用はBRAF V600E変異肺癌細胞株のアポトーシスを亢進させる(Novel TEAD1 inhibitor VT103 plus dabrafenib promotes apoptosis in BRAF V600E mutated lung adenocarcinoma cell lines)

  細谷 和貴; 小笹 裕晃; 橋本 健太郎; 吉田 寛; 大木元 達也; 味水 瞳; 船造 智子; 吉田 博徳; 野溝 岳; 辻 貴宏; Tracy Tang T.; 平井 豊博

  日本癌学会総会記事, Sep. 2023

  
• 新規TEAD1阻害薬VT103はALK陽性肺癌細胞株に対するTKIの効果を増幅する(Novel TEAD1 inhibitor VT103 may enhance efficacy of ALK-TKI in lung cancer cell line in vitro and in vivo)

  橋本 健太郎; 小笹 裕晃; 山添 正敏; 吉田 寛; 大木元 達也; 細谷 和貴; 船造 智子; 味水 瞳; 吉田 博徳; 野溝 岳; Tang Tracy T.; 平井 豊博

  日本癌学会総会記事, Sep. 2023

  
• CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer

  Tatsuya Ogimoto; Hiroaki Ozasa; Hironori Yoshida; Takashi Nomizo; Tomoko Funazo; Hiroshi Yoshida; Kentaro Hashimoto; Kazutaka Hosoya; Masatoshi Yamazoe; Hitomi Ajimizu; Takahiro Tsuji; Yuichi Sakamori; Kiyomitsu Kuninaga; Satoshi Morita; Toyohiro Hirai

  Oncology Letters, 10 Jul. 2023

  
• Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.

  Hitomi Ajimizu; Hiroaki Ozasa; Susumu Sato; Tomoko Funazo; Yuichi Sakamori; Takashi Nomizo; Kiyomitsu Kuninaga; Tatsuya Ogimoto; Kazutaka Hosoya; Masatoshi Yamazoe; Takahiro Tsuji; Hironori Yoshida; Ryo Itotani; Kentaro Ueno; Young Hak Kim; Shigeo Muro; Toyohiro Hirai

  Scientific reports, 06 Feb. 2023

  
• Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.

  Yamazoe M; Hiroaki Ozasa; Takahiro Tsuji; Funazo T; Yoshida H; Hashimoto K; Kazutaka Hosoya; Ogimoto T; Ajimizu H; Yoshida H; Itotani R; Sakamori Y; Kuninaga K; Wataru Aoki; Hirai T

  Cancer science, 23 Nov. 2022, Peer-reviewed

  
• Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.

  Hashimoto K; Hiroaki Ozasa; Yoshizawa A; Yoshida H; Ogimoto T; Kazutaka Hosoya; Yamazoe M; Ajimizu H; Funazo T; Yoshida H; Sakamori Y; Hirai T

  Oncology letters, 22 Sep. 2022, Peer-reviewed

  
• YAP1やその他の因子はEGFR遺伝子変異陽性肺癌の初期耐性機序と関連する(YAP1 and other factors are associated with initial resistance mechanisms in EGFR mutation-positive lung cancer)

  大木元 達也; 小笹 裕晃; 橋本 健太郎; 吉田 寛; 細谷 和貴; 山添 正敏; 味水 瞳; 船造 智子; 辻 貴宏; 吉田 博徳; 阪森 優一; 平井 豊博

  日本癌学会総会記事, Sep. 2022

  
• 患者由来BRAF V600E変異陽性肺癌細胞株に対し、新規TEAD1阻害薬VT103がアポトーシスを促進する(Novel TEAD1 inhibitor VT103 promotes apoptosis in patient-derived BRAF V600E mutated lung adenocarcinoma cell lines)

  細谷 和貴; 小笹 裕晃; 橋本 健太郎; 吉田 寛; 大木元 達也; 山添 正敏; 味水 瞳; 船造 智子; 辻 貴宏; 吉田 博徳; 阪森 優一; Tracy Tang T.; 平井 豊博

  日本癌学会総会記事, Sep. 2022

  
• YAP1はAKTシグナルを介してROS1肺癌におけるROS1阻害薬からの初期生存に関与する(YAP1 mediates initial cell survival during lorlatinib treatment via AKT signaling in ROS1-rearranged lung cancer)

  山添 正敏; 小笹 裕晃; 辻 貴宏; 船造 智子; 吉田 寛; 橋本 健太郎; 細谷 和貴; 大木元 達也; 味水 瞳; 吉田 博徳; 糸谷 涼; 阪森 優一; 國永 清光; 平井 豊博

  日本癌学会総会記事, Sep. 2022

  
• Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.

  Ajimizu H; Hiroaki Ozasa; Sato S; Funazo T; Sakamori Y; Nomizo T; Kuninaga K; Ogimoto T; Kazutaka Hosoya; Yamazoe M; Tsuji T; hironori yoshida; Itotani R; Ueno K; Kim YH; Muro S; Hirai T

  Scientific reports, 08 Dec. 2021, Peer-reviewed

  
• 二光子顕微鏡による肺癌肝転移モデルの観察

  味水 瞳; 小笹 裕晃; 辻 貴宏; 橋本 健太郎; 吉田 寛; 大木元 達也; 細谷 和貴; 山添 正敏; 船造 智子; 糸谷 涼; 吉田 博徳; 和氣 弘明; 平井 豊博

  日本癌学会総会記事, Sep. 2021

  
• BRAF V600E変異陽性肺癌の分子標的薬耐性に上皮間葉転換(EMT)が関与する

  細谷 和貴; 小笹 裕晃; 橋本 健太郎; 吉田 寛; 大木元 達也; 山添 正敏; 味水 瞳; 船造 智子; 辻 貴宏; 吉田 博徳; 阪森 優一; 平井 豊博

  日本癌学会総会記事, Sep. 2021

  
• CD47のSNPsが肺癌のニボルマブの治療効果に影響を与える

  大木元 達也; 小笹 裕晃; 橋本 健太郎; 吉田 寛; 細谷 和貴; 山添 正敏; 味水 瞳; 船造 智子; 辻 貴宏; 吉田 博徳; 阪森 優一; 平井 豊博

  日本癌学会総会記事, Sep. 2021

  
• Activation of YAP1 confers ROS1 inhibitor resistance in ROS1-rearranged lung cancer

  Masatoshi Yamazoe; Hiroaki Ozasa; Tetsuya Ohgimoto; Kazutaka Hosoya; Hitomi Ajimizu; Tomoko Funazo; Yuto Yasuda; Takahiro Tsuji; Hironori Yoshida; Ryo Itotani; Yuichi Sakamori; Young Hak Kim; Hirai Toyohiro

  CANCER RESEARCH, Jul. 2021

  
• ROS1陽性肺癌においてYAP1はROS1阻害薬からの初期生存に関与する

  山添 正敏; 小笹 裕晃; 辻 貴宏; 船造 智子; 大木元 達也; 細谷 和貴; 味水 瞳; 安田 有斗; 吉田 博徳; 阪森 優一; 金 永学; 平井 豊博

  日本呼吸器学会誌, Apr. 2021

  
• Activation of YAP1 confers ROS1 inhibitor resistance in ROS1-rearranged lung cancer

  Masatoshi Yamazoe; Hiroaki Ozasa; Tatsuya Ogimoto; Kazutaka Hosoya; Hitomi Ajimizu; Yuto Yasuda; Tomoko Funazo; Takahiro Tsuji; Hironori Yoshida; Yuichi Sakamori; Young Hak Kim; Toyohiro Hirai

  CANCER SCIENCE, Feb. 2021

  
• PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.

  hironori yoshida; Nomizo T; Hiroaki Ozasa; Tsuji T; Funazo T; Yasuda Y; Ajimizu H; Yamazoe M; Kuninaga K; Ogimoto T; Kazutaka Hosoya; Itotani R; Sakamori Y; Kim YH; Hirai T

  European journal of cancer (Oxford, England : 1990), 30 Dec. 2020, Peer-reviewed

  
• Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.

  Tomoko Funazo; Takahiro Tsuji; Hiroaki Ozasa; Furugaki K; Yoshimura Y; Oguri T; Ajimizu H; Yuto Yasuda; Nomizo T; Sakamori Y; hironori yoshida; Kim YH; Hirai T

  Molecular cancer therapeutics, 26 Mar. 2020, Peer-reviewed, Lead author

  
• MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X_L expression.

  Yuto Yasuda; Hiroaki Ozasa; Kim YH; Yamazoe M; Ajimizu H; Yamamoto Funazo T; Nomizo T; Takahiro Tsuji; hironori yoshida; Sakamori Y; Nakajima N; Toshi Menju; Yoshizawa A; Date H; Hirai T

  Cell death & disease, 09 Mar. 2020, Peer-reviewed

  Access this paper :

  
• YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation

  Takahiro Tsuji; Hiroaki Ozasa; Wataru Aoki; Shunsuke Aburaya; Tomoko Yamamoto Funazo; Koh Furugaki; Yasushi Yoshimura; Masatoshi Yamazoe; Hitomi Ajimizu; Yuto Yasuda; Takashi Nomizo; Hironori Yoshida; Yuichi Sakamori; Hiroaki Wake; Mitsuyoshi Ueda; Young Hak Kim; Toyohiro Hirai

  Nature Communications, 03 Jan. 2020, Peer-reviewed

  Access this paper :

  
• Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab

  Tomoko Yamamoto Funazo; Takashi Nomizo; Hiroaki Ozasa; Takahiro Tsuji; Yuto Yasuda; Hironori Yoshida; Yuichi Sakamori; Hiroki Nagai; Toyohiro Hirai; Young Hak Kim

  Scientific Reports, 19 Nov. 2019, Peer-reviewed, Lead author

  Access this paper :

  
• Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer.

  hironori yoshida; Kim YH; Hiroaki Ozasa; Sakamori Y; Takahiro Tsuji; Nomizo T; Yasuda Y; Yamamoto T; Hitomi Ajimizu; Hirai T

  In vivo (Athens, Greece), 01 Nov. 2018, Peer-reviewed

  
• Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model.

  Takahiro Tsuji; Hiroaki Ozasa; Wataru Aoki; Shunsuke Aburaya; Funazo T; Furugaki K; Yoshimura Y; Hitomi Ajimizu; Okutani R; Yasuda Y; Nomizo T; Kiyoshi Uemasu; Hasegawa K; hironori yoshida; Yagi Y; Nagai H; Sakamori Y; Ueda M; Hirai T; Kim YH

  Molecular cancer research : MCR, 31 Aug. 2018, Peer-reviewed

  
• Efficacy of MCL1 inhibitor S63845 in small cell lung cancer

  Yuto Yasuda; Hiroaki Ozasa; Takahiro Tsuji; Takashi Nomizo; Tomoko Funazo; Hironori Yoshida; Yuichi Sakamori; Toyohiro Hirai; Young Hak Kim

  CANCER RESEARCH, Jul. 2018

  
• Abstract 1830: A clinical paired resistant model elucidated novel dual salvage signaling that confers alectinib resistance in ALK-rearranged lung cancer

  Takahiro Tsuji; Hiroaki Ozasa; Takashi Nomizo; Tomoko Funazo; Yuto Yasuda; Yuichi Sakamori; Hironori Yoshida; Kiyoshi Uemasu; Hitomi Ajimizu; Ryoko Okutani; Shunsuke Aburaya; Wataru Aoki; Mitsuyoshi Ueda; Koh Furugaki; Yasushi Yoshimura; Toyohiro Hirai; Young Hak Kim

  Cancer Research, 01 Jul. 2018

  
• Nivolumab in non-small-cell lung cancer with EGFR mutation.

  hironori yoshida; Kim YH; Hiroaki Ozasa; Nagai H; Sakamori Y; Takahiro Tsuji; Nomizo T; Yasuda Y; Funazo T; Hirai T

  Annals of oncology : official journal of the European Society for Medical Oncology, 01 Mar. 2018, Peer-reviewed

  
• Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease.

  Yuto Yasuda; Takashi Nomizo; Hiroaki Ozasa; Tomoko Funazo; Takahiro Tsuji; Hironori Yoshida; Yuichi Sakamori; Hiroki Nagai; Tomohiro Handa; Takeshi Kubo; Young Hak Kim

  Molecular and clinical oncology, Oct. 2017, Peer-reviewed

  
• Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.

  Tomoko Funazo; Nomizo T; Kim YH

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 01 Sep. 2017, Peer-reviewed, Lead author

  
• Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer.

  Funazo T; Morita K; Ikegami N; Konishi C; Nakao S; Ariyasu R; Taki M; Nakagawa K; Hwang MH; Yoshimura C; Wakayama T; Nishizaka Y

  Internal medicine (Tokyo, Japan), 10 Aug. 2017, Peer-reviewed, Lead author

  
• Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.

  Yuto Yasuda; Nishikawa Y; Sakamori Y; Terao M; Hashimoto K; Funazo T; Nomizo T; Takahiro Tsuji; hironori yoshida; Nagai H; Ozasa H; Hirai T; Kim YH

  Molecular and clinical oncology, 29 Jun. 2017, Peer-reviewed

  
• Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.

  Takahiro Tsuji; Sakamori Y; Hiroaki Ozasa; Yagi Y; Hitomi Ajimizu; Yasuda Y; Funazo T; Nomizo T; hironori yoshida; Nagai H; Maeno K; Oguri T; Hirai T; Kim YH

  Oncotarget, 16 May 2017, Peer-reviewed

  Access this paper :

  
• EGFRT790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.

  hironori yoshida; Kim YH; Hiroaki Ozasa; Nagai H; Sakamori Y; Takahiro Tsuji; Nomizo T; Funazo T; Yasuda Y; Hirai T

  Anticancer research, 01 May 2017, Peer-reviewed

  
• Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.

  Nomizo T; Hiroaki Ozasa; Takahiro Tsuji; Funazo T; Yasuda Y; hironori yoshida; Yagi Y; Sakamori Y; Nagai H; Hirai T; Kim YH

  Scientific reports, 23 Mar. 2017, Peer-reviewed

  Access this paper :

  
• Varicella Reinfection with Unilateral Varicella Pneumonia.

  Ariyasu R; Nakagawa K; Ikegami N; Konishi C; Nakao S; Funazo T; Taki M; Morita K; Hwang MH; Yoshimura C; Wakayama T; Nishizaka Y

  Internal medicine (Tokyo, Japan), 01 Nov. 2016, Peer-reviewed

  
• Pulmonary Sarcoidosis Presenting with Miliary Opacities

  Masato Taki; Naoya Ikegami; Chisato Konishi; Satoshi Nakao; Tomoko Funazou; Ryo Ariyasu; Masanori Yoshida; Kazuhiko Nakagawa; Kyouhei Morita; Moon Hee Hwang; Chie Yoshimura; Toshiaki Wakayama; Yasuo Nishizaka

  Internal Medicine, 2015, Peer-reviewed

  
• Prolonged disturbance of consciousness caused by severe hypophosphatemia: a report of two cases.

  Murakami T; Yoshida M; Funazo T; Matsuda Y; Matsuo K; Nambu T; Yonemitsu S; Muro S; Oki S

  Internal medicine (Tokyo, Japan), 01 Jan. 2014, Peer-reviewed

  

Misc.

• YAP1 and other factors are associated with initial resistance mechanisms in EGFR mutation-positive lung cancer

  大木元達也; 小笹裕晃; 橋本健太郎; 吉田寛; 細谷和貴; 山添正敏; 味水瞳; 船造智子; 辻貴宏; 辻貴宏; 吉田博徳; 阪森優一; 平井豊博

  日本癌学会学術総会抄録集(Web), 2022

  
• Novel TEAD1 inhibitor VT103 promotes apoptosis in patient-derived BRAF V600E mutated lung adenocarcinoma cell lines

  細谷和貴; 小笹裕晃; 橋本健太郎; 吉田寛; 大木元達也; 山添正敏; 味水瞳; 船造智子; 辻貴宏; 辻貴宏; 吉田博徳; 阪森優一; TRACY Tang T.; 平井豊博

  日本癌学会学術総会抄録集(Web), 2022

  
• Single nucleotide polymorphisms in PD-L1 and outcome in nivolumab-treated advanced non-small-cell lung cancer patients

  T. Nomizo; T. Funazo; H. Ozasa; T. Tsuji; Y. Yasuda; H. Yoshida; Y. Sakamori; H. Nagai; T. Hirai; Y. H. Kim

  ANNALS OF ONCOLOGY, Sep. 2017

  
• 当院におけるオシメルチニブの使用経験

  吉田博徳; 船造智子; 安田有斗; 野溝岳; 辻貴宏; 阪森優一; 永井宏樹; 小笹裕晃; 金永学

  肺癌(Web), 2017

  
• 免疫チェックポイント阻害剤の副作用マネージメント

  永井宏樹; 船造智子; 安田有斗; 野溝岳; 辻貴宏; 吉田博徳; 阪森優一; 小笹裕晃; 金永学

  肺癌(Web), 2017

  
• COPD合併非小細胞肺癌の予後

  味水 瞳; 小笹 裕晃; 佐藤 晋; 阪森 優一; 船造 智子; 安田 有斗; 野溝 岳; 辻 貴宏; 八木 由生; 吉田 博徳; 永井 宏樹; 佐藤 篤靖; 土谷 美知子; 室 繁郎; 長坂 行雄; 三嶋 理晃; 金 永学

  肺癌, Nov. 2016

  
• 京大病院におけるチーム医療の取り組みと安全性対策 免疫チェックポイント阻害剤を安全に使用するために

  永井 宏樹; 金 永学; 大塚 篤司; 寺尾 真琴; 池見 泰明; 黒田 貴子; 浜辺 陽子; 安田 有斗; 船造 智子; 野溝 岳; 辻 貴宏; 八木 由生; 吉田 博徳; 阪森 優一; 小笹 裕晃; 松本 繁巳; 武藤 学

  肺癌, Nov. 2016

  
• Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer

  H. Ajimizu; H. Ozasa; S. Sato; Y. Sakamori; T. Funazo; Y. Yasuda; T. Nomizo; T. Tsuji; H. Yoshida; Y. Yagi; H. Nagai; A. Sato; M. Tsuchiya; S. Muro; Y. Nagasaka; M. Mishima; Y. H. Kim

  ANNALS OF ONCOLOGY, Oct. 2016

  
• 当院におけるALK融合遺伝子転座陽性進行非小細胞肺癌の使用経験

  安田 有斗; 辻 貴宏; 船造 智子; 野溝 岳; 八木 由生; 吉田 博徳; 阪森 優一; 永井 宏樹; 小笹 裕晃; 金 永学

  第104回日本肺癌学会関西支部学術集会, Jul. 2016

  

Awards

• 08 Feb. 2021

  Medical Prize in Research Fields.奨励賞（NPO法人西日本呼吸器内科医療推進機構）

External funds: Kakenhi

• Identification of factors involved in intratumor heterogeneity using patient-derived lung cancer cell lines

  Grant-in-Aid for Early-Career Scientists

  Basic Section 53030:Respiratory medicine-related

  Kyoto University

  船造 智子

  From 01 Apr. 2023, To 31 Mar. 2026, Granted

  腫瘍内不均一性;薬剤修飾;患者由来肺癌細胞株;アレクチニブ;ダブラフェニブ;非小細胞肺癌;患者由来癌細胞株;ALK陽性肺癌

  https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23K15186/